[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-370646-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-370646-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-deubiquitinase-usp7-stabilizes-her2-expression-and-cancer-progression","The deubiquitinase USP7 stabilizes HER2 expression and cancer progression","","The overexpression and amplification of HER2 drive breast cancer, yet the deubiquitinating enzyme governing HER2 stability remains unclear. Using MTS, Western blot, CoIP, colony formation, RT-qPCR, EdU, flow cytometry, immunofluorescence, and xenograft assays, the study shows USP7 deletion reduces HER2 protein abundance and inhibits growth of HER2-positive breast cancer cells. USP7 correlates with HER2 in tumors, accelerates cell-cycle progression, and stabilizes HER2 by lowering HER2 ubiquitination; USP7 knockdown suppresses tumor growth in vitro and in vivo, and HER2 overexpression partially rescues.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-deubiquitinase-usp7-stabilizes-her2-expression-and-cancer-progression/370646/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-deubiquitinase-usp7-stabilizes-her2-expression-and-cancer-progression/370646.png","ImageObject",300,407,{"name":42,"@type":43},"นรินทร์","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How does USP7 influence HER2 stability in HER2-positive breast cancer?","Question",{"text":63,"@type":64},"USP7 interacts with HER2 and decreases HER2 ubiquitination, which stabilizes HER2 expression and supports malignant progression.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What is the effect of deleting or knocking down USP7 on cancer cell growth?",{"text":68,"@type":64},"USP7 deletion inhibits growth of HER2-positive breast cancer cells by lowering HER2 protein abundance, and USP7 knockdown suppresses tumor growth both in vivo and in vitro.",{"name":70,"@type":61,"acceptedAnswer":71},"Does restoring HER2 activity counteract USP7 inhibition?",{"text":72,"@type":64},"Yes. HER2 overexpression partially reverses cell growth inhibition induced by USP7 inhibition.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},370646,1790216117,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},2336475104957,"https://ap-avatar.wpscdn.com/avatar/22000c4c6bd8a5076e1?x-image-process=image/resize,m_fixed,w_180,h_180&k=1787554080175789136","Neoplasia 66 (2025) 101192  \nContents lists available at ScienceDirect  \nNeoplasia  \njournal [homepage:](homepage: www.elsevier.com/locate/neo)[ www.elsevier.com/locate/neo](homepage: www.elsevier.com/locate/neo)  \n| Original Research\u003Cbr>The deubiquitinase USP7 stabilizes HER2 expression and cancer progression |  |  | promotes breast | |\n| --- | --- | --- | --- | --- |\n| Xiaoyue He a,b,1, Xiaohong Xiaa,1, Ziying Leia,1, Mengfan Tanga,b, Jiangyu Zhang a,*, Yuning Liao a,b,*, Hongbiao Huang a,b,* \u003Cbr>a Guangzhou Institute of Cancer Research, the Affiliated Cancer Hospital, Guangzhou Medical University, Guangzhou 510095, PR China\u003Cbr>b Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou 511436, PR China |  |  |  |  |\n| A R T I C L E I N F O |  | A B S T R A C T |  |  |\n| Keywords: USP7\u003Cbr>HER2 Positive breast cancer Ubiquitination\u003Cbr>Growth |  | The overexpression and amplification of HER2 occurs in breast cancer. However, the mechanism of HER2 action in tumor has not yet been elucidated. HER2 can be degraded by the UPS system, and several HER2-associated E3shave been identified, but the DUB for HER2 has not yet been uncovered. Targeted therapy against HER2 has achieved impressive efficacy in patients with HER2-positive breast cancer. Herein, using MTS, Western blot, CoIP, colony formation, RT‒qPCR, EdU, flow cytometry, immunofluorescence assays and xenograft model, we elucidated that USP7 deletion inhibited the growth of HER2-positive breast cancer cell by decreasing HER2 protein abundance. We found that USP7 was highly expressed in HER2-positive breast cancer and the expression of USP7 and HER2 was positively correlated. USP7 overexpression accelerated cell cycle progression. Mechanistically, USP7 interacted with HER2 and decreased HER2 ubiquitination to stabilize its expression. Moreover, USP7 knockdown inhibited tumor growth in vivo and in vitro. In addition, HER2 overexpression partially reversed cell growth inhibition induced by USP7 inhibition. Analyses of clinical samples revealed that USP7 overexpression was associated with poor prognosis in patients with HER2+ breast cancer. Thus, this study revealed that USP7, as a DUB of HER2, may be a potential therapeutic target for patient with HER2+ breast cancer. |  |  |\n\nIntroduction  \nFemale breast cancer is one of the most prevalent cancers in the world and has one of the highest morbidity and mortality rates [1]. Breast cancer can be divided into four categories according to molecular type: HER2-positive (HER2+ ), luminal A, luminal B, and basal-like [2]. Approximately 25-30 % of breast cancers exhibit HER2 protein overexpression, either through gene amplification or through transcriptional dysregulation, resulting in worse biological behavior and a poorer prognosis. However, in recent years, with advances in HER2-targeted therapies [3], the overall survival rates of patients diagnosed with HER2-positive breast cancer have increased [4,5].  \nHER2, a proto-oncogene located on chromosome 17 and encoded by ERBB2, is a member of the EGFR family, which comprises four distinct members: HER1 (EGFR), HER2, HER3, and HER4 [6]. Studies have provided insight into the mechanisms of tumorigenesis and  \ndevelopment that are dependent on abnormalities in various ERBB signaling pathways [7]. Through interactions with growth factors, HER2 is phosphorylated, activating downstream kinases. HER2 comprises four plasma membrane-bound receptor tyrosine kinases and participates in intracellular signaling pathways that are involved in cell proliferation, survival, migration and polarization. Mechanism of HER2-induced tumor formation include hyperactivation and overexpression of HER2. Numerous studies have identified the inhibition of tumor development through HER2 degradation as an effective therapeutic strategy. HER2 can be regulated by ubiquitin-mediated degradation through the ","cbCaioJUUeC2hTyb","https://ap.wps.com/l/cbCaioJUUeC2hTyb","pdf",10805433,11,"English","# Introduction\n## HER2 in breast cancer\n## Ubiquitin–proteasome system and DUBs\n## Study rationale\n# Materials and methods","[{\"question\":\"How does USP7 influence HER2 stability in HER2-positive breast cancer?\",\"answer\":\"USP7 interacts with HER2 and decreases HER2 ubiquitination, which stabilizes HER2 expression and supports malignant progression.\"},{\"question\":\"What is the effect of deleting or knocking down USP7 on cancer cell growth?\",\"answer\":\"USP7 deletion inhibits growth of HER2-positive breast cancer cells by lowering HER2 protein abundance, and USP7 knockdown suppresses tumor growth both in vivo and in vitro.\"},{\"question\":\"Does restoring HER2 activity counteract USP7 inhibition?\",\"answer\":\"Yes. HER2 overexpression partially reverses cell growth inhibition induced by USP7 inhibition.\"}]","The deubiquitinase USP7 stabilizes HER2 expression and cancer progression | PDF",1790189616,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7c2954854e998dde3680887150d781c8.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e6c722e44e5e1f86ab6634a7c2dfc1b5.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1c6133b66c45275d5a049d2bdc01273b.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ff6de13bb0e9dd0a4db20c4ee8145783.webp",980,1306]